Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DocTIS trial of add-on tocilizumab in active rheumatoid arthritis or psoriatic arthritis on TNF inhibitors
ISRCTN50666516Phase 2Active, not recruiting
- Sponsor
- Cardiff University
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA) and psoriatic arthritis (PsA), sponsored by Cardiff University. Primary endpoint: Disease remission at week 24. Started Apr 2025; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on ISRCTN50666516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50666516.